Expression of Genetically Modified Human Papillomavirus Type 58 L 1 Gene and Production of Antisera Against Resultant VLP
|
|
- Nathaniel Williams
- 5 years ago
- Views:
Transcription
1 ISSN CN ΠQ Chinese Journal of Biochemistry and Molecular Biology (7) : HPV 58 L1 VLP,,,,,, 3 (, ) (human papillomavirus, HPV). HPV (L1) (virus2like particle, VLP),,,. HPV 58, HPV 58. HPV 58 L1, HPV 58 L1, HPV 58 ml1, 2 HPV 58 ml1,cscl HPV 58 ml1,, 55 nm VLP.,ELISA, HPV 58 ml1 VLP,, VLP. HPV 58 ml1 VLP, HPV 58 ml1 VLP, HPV ; ; ; R37319 ;Q786 Expression of Genetically Modified Human Papillomavirus Type 58 L 1 Gene and Production of Antisera Against Resultant VLP FAN Dong2Sheng, ZHANG Ting, PENG Qing2Lin, YANGLi2Jun, XU Yu2Fei, ZHANG Ran, XU Xue2Mei 3 ( Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing , China) Abstract Persistent infection with high2risk types of human papillomavirus has been proved as an important etiological factor for cervical cancer. HPV major capsid protein (L1) can self2assemble into VLPs when expressed in a recombinant expression system. VLP can induce high levels of type2specific neutralizing antibodies to efficiently prevent the infection of the same genotype HPV and eventually prevent cervical cancer and other infection related diseases. HPV type 58 is one of the most common high2risk HPVs in Chinese cervical cancer patients. However, there is no effective vaccine to prevent HPV 58 infection so far. The HPV 58 L1 wt gene was modified by several strategies. The modified gene, named as HPV 58 ml1, was expressed by Baculovirus Expression System, and the recombinant protein was purified by CsCl ultracentrifugation. The transmission electron microscopy analysis showed that the recombinant HPV 58 ml1 protein could self2assemble into regular VLP with a diameter of about 55 nm. New Zealand white rabbit and guinea pigs were subcutaneously immunized with HPV 58 ml1 VLP. VLP ELISA showed that HPV 58 VLP could induce high titers of HPV 58 ml1 VLP specific antibodies. Dot blot assay indicated that the sera antibodies were against the surface epitopes of VLP. Taken together, HPV 58 ml1 VLP was produced by Baculovirus Expression : ; : (863,No. 2007AA02Z475) (No ) 3 Tel : ; E2mail : sina. com Received : February 15,2009 ; Accepted : April 3,2009 Supported by National High Technology Research and Development Program of China ( 863 Program, No. 2007AA02Z475) and National Natural Science Foundation of China (No ) 3 Corresponding author Tel : ; E2mail : sina. com
2 System and antisera were obtained from two different species, which were important for further developing effective HPV 58 VLP based prophylactic vaccines. Key words human papillomavirus type 58 ;virus2like particle ;gene modification ;antisera (human papillomavirus, HPV) DNA,,, 118 [1 ], HPV 15, HPV [2 ],, [1 ]., 50, 27., 416, 216 [3 ]., HPV [4 ], HPV., HPV L1 L1 (L2) (virus2like particle, VLP),VLP,, HPV [5 ]. HPV L1 VLP, HPV ( HPV 18 45,HPV ), HPV L1 VLP [1 ].,, HPV. 25 ( ) 3607, 3 HPV 16 ( 5315 %), 18 (1712 %) 45 (617 %), HPV58 7 (212 %) [1 ], 5954, HPV %, HPV 16 (5214 %) 18 (1415 %) [6 ], ,HPV % [3 ],, HPV 58. L1 VLP HPV, Gardasil ( HPV 16Π18Π6Π11 L1 VLPs) Cervarix( HPV 16Π18 L1 VLPs) HPV, HPV 58 L1 VLP. VLP HPV. HPV 58 ml1, 2 HPV 58 ml1 VLP, HPV 58 ml1 VLP, HPV 58 L1 VLP pfastbac1 E. coli DH10Bac Sf9 Invitrogen, HPV 16 ml1 ( HPV 16 L1, L1 C 31 ) SF2900II SFM Cellfectin Reagent Invitrogen ;CamVir21 IgG IgG IgG ;CsCl Amerasco ; R250 ; 300 ; BCA Pierce ; Corning ; ECL Transgen ,,6 8, 212 kg, ; 2,,6 8, 300 g,. 114 HPV 58 L1 HPV 58 L1 (D90400), C 25, : Sf9 ; mrna,,, HPV 58 L1, HPV 58 ml1. HPV 58 ml1. Kozak, HPV 58 ml1 pfastbac HPV 58 ml1
3 7 :HPV 58 L1 VLP 679 Bac2to2Bac 2, pfastbac1πhpv 58 ml1 E. coli DH10Bac, PCR, HPV 58 ml1 Bacmid (rbacmid). rbacmid, Cellfectin Reagent, Sf9. 3 d, 2, Sf9., 10 % SDS2PAGE, Western HPV 58 ml1, Sf9, HPV 16 ml1, CamVir21 ( ),ECL. 116 HPV 58 ml1,4,800 rπmin 6 min,,,4, CsCl VLP [7 ]. Western 10 mmolπl HEPES(pH 712),BCA. 5 g VLP 10 % SDS2PAGE, VLP. 20 l VLP 300,1 min, 20 l 1 %, J EM21010, VLP g HPV 58 ml 1 VLP 500 l,,, ; 20 g HPV 58 ml1 VLP 200 l,,, ,,. 1 1,, ELISA,,, IgG ELISA 100 ng HPV 58 ml1 VLPΠ 96,,,, IgG IgG, , OPD,37 5 min, 2 molπl H 2 SO 4, 490 nm. A HPV 58 ml1 VLP 014 g VLP, VLP 95 5 min, 5 % TBST 1 h, HPV 58 ml1 VLP HPV 58 ml1 VLP, ,4, TBST 3, IgG IgG, , 1 h,tbst 3,ECL HPV 58 ml1 Western Western, HPV 58 ml1 Sf9 53 kd, HPV 58 ml1, HPV 16 ml1 Sf9, Sf9 ( Fig. 1), HPV 58 ml1. Fig. 1 Western blot assay of HPV 58 ml1 protein expression in Sf9 cells Lysate from Sf9 cells (lane 1), Sf9 cells infected with rbaculovirus HPV 16 ml1 (lane 2) or HPV 58 ml1 (lane 3) were separated by 10 % SDS2PAGE. Proteins were transferred onto PVDF membrane and probed with CamVir21 mab at a dilution of The membrane was incubated with goat anti2mouse peroxidase2conjugated secondary antibody at a dilution of and processed by the enhanced chemiluminescence detection method. Protein markers are shown on the left. The position of the L1 protein (53 kd) is indicated by the arrow on the right 2. 2 VLP,5 g L1, SDS2PAGE, 53 kd, (Fig. 2),, 90 % , HPV 58
4 Fig. 2 Purified HPV 58 ml1 analyzed by 10 % SDS2PAGE with Coomassie blue staining Protein marker (lane 1) and purified HPV 58 ml1 ( lane 2) were separated by 10 % SDS2PAGE and stained with Coomassie blue. The 53 kd HPV 58 ml1 band is indicated by the arrow ml1 55 nm, (Fig. 3), HPV, HPV 58 ml1 VLP. Fig. 4 ELISA of antisera from New Zealand white rabbit and guinea pigs immunized with HPV 58 ml1 VLPs New Zealand white rabbit or guinea pigs were immunized three times with 50 g HPV 58 ml1 VLP or four times with 20 g the VLP, respectively. The post2immune sera were detected by VLP ELISA. ( A) The anti2hpv 58 ml1 VLP antibody titer of antiserum from New Zealand white rabbit. (B) The anti2hpv 58 ml1 VLP antibody titers of antisera from guinea pigs Fig. 3 Electron micrograph of purified HPV 58 ml1 VLPs Grids were stained with 1 % uranyl acetate and examined with a J EM 1010 electron microscope at magnification (bar = 100 nm) 2. 4 IgG HPV 58 ml1 VLP 96,ELISA HPV 58 ml1 VLP IgG. Fig. 4A 4B HPV 58 ml1 VLP IgG , HPV 58 VLP HPV 58 ml1 VLP, , HPV 58 ml1 VLP,, HPV 58 ml1 VLP, VLP (Fig. 5), VLP. 3 HPV 72 L1 12 L2 T = 7, 60 nm. HPV,, [8 ].,L1,, L1, T = 1 T = 4 VLP( L1 ), T = 7 VLP [9 11 ]. L1
5 7 :HPV 58 L1 VLP 681 Fig. 5 Dot blot assay Purified intact (1 and 3) and denatured HPV 58 ml1 VLPs (2 and 4) were directly loaded onto the nitrocellulose membrane. (A) Proteins were probed with the antiserum from New Zealand white rabbit, followed by goat anti2rabbit peroxidase2conjugated secondary antibody. (B) Proteins were probed with the mixture of antisera from guinea pigs, followed by rabbit anti2guinea pig peroxidase2conjugated secondary antibody. Both of membranes were detected by the enhanced chemiluminescence detection method, L1 L1 VLP [12 ]. VLP, T = 4 [10 ], VLP, T = 7 [11 ],., L1 VLP. HPV 58 L1,. 2, HPV 58 ml1, HPV 58 ml1 VLP.,L1 C 30,, DNA, [1 ], C, BPV L1 C 24 [13 ], HPV 16 L1 C 30 [9 ] VLP, L1 [13 ].,, mrna., HPV 58 L1,, Sf9 mrna Kozak HPV 58 L1 C 25, HPV 58 ml1, 2. CamVir21 HPV 16 L1 (L1 a. a GFGAMDF) [14 ], HPV, HPV 58 L1 1, HPV 58 L1 VLP, CamVir21 Western HPV 58 ml1, HPV 58 L1 [15 ]. HPV 58 L1 VLP, HPV 58 L1 VLP, HPV 58 L1 VLP. L1 VLP HPV 58, Cervarix HPV % ( 9719 % CI, % 2417 %) [16 ], Gardasil HPV 16 HPV % (95 % CI, 8 % 52 %) [17 ], HPV HPV 58. VLP,,. 75 g HPV 58 L1, 0 1 5, [15 ], 50 g 20 g HPV 58 ml1 VLP, VLP IgG , HPV 58 ml1 VLP, VLP, VLP. HPV 58 L1.,, T = 7 VLP [18 ], T = 1 VLP [9 ], L1 [12 ],, L1
6 [18 ],. HPV 58, HPV 58 ml1 VLP HPV 58 L1 VLP.. ( References) [ 1 ]. : 2008 [J ]. ( Xu Xue2 Mei. Human papillomaviruses and cervical cancer vaccines : to decode 2008 Nobel Prize in physiology or medicine[j ]. Prog Biochem Biophys), 2008, 35 (10) : [ 2 ] Roden R, Wu T C. How will HPV vaccines affect cervical cancer? [J ] Nat Rev Cancer, 2006,6(10) : [ 3 ] Castellsagu X, de Sanjos S, Aguado T, et al. HPV and cervical cancer in the world 2007 report [J ]. Vaccine, 2007, 25 (S3) : C12 C26 [ 4 ] Bosch F X, Lorincz A, Mugoz N, et al. The causal relation between human papillomavirus and cervical cancer[j ]. J Clin Pathol, 2002, 55(4) : [ 5 ] Mao C, Koutsky L A, Ault K A, et al. Efficacy of human papillomavirus216 vaccine to prevent cervical intraepithelial neoplasia : a randomized controlled trial [J ]. Obstet Gynecol, 2006, 107(1) :18227 [ 6 ] Bao Y P, Li N, Smith J S, et al. Human papillomavirus type distribution in women from Asia : a meta2analysis[j ]. Int J Gynecol Cancer, 2008,18(1) :71279 [ 7 ] Shi W, Liu J, Huang Y, et al. Papillomavirus pseudovirus : a novel vaccine to induce mucosal and systemic cytotoxic T2lymphocyte responses[j ]. J Virol, 2001,75 (21) : [ 8 ] Fleury M J, Touz A, Alvarez E, et al. Identification of type2 specific and cross2reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31 [ J ]. Virol, 2006,151(8) : Arch [ 9 ] Chen X S, Garcea R L, Goldberg I, et al. Structure of small virus2 like particles assembled from the L1 protein of human papillomavirus 16[J ]. Mol Cell, 2000,5(3) : [10 ] Mukherjee S, Thorsteinsson M, Johnston L B, et al. A quantitative description of in vitro assembly of human papillomavirus 16 virus2like particles [J ]. J Mol Biol, 2008,381(1) : [11 ] Rose R C, Bonnez W, Reichman R C, et al. Expression of human papillomavirus type 11 L1 protein in insect cells : In vivo and in vitro assembly of virus2like particles [J ]. J Virol, 1993, 67 (4) : [12 ] Thgnes N, Herreiner A, Schgdlich L, et al. A direct comparison of human papillomavirustype 16 L1 particles reveals a lower immunogenicity of capsomeres than virus2like particles with respect to the induced antibody response[j ]. J Virol, 2008,82 (11) : [13 ] Paintsil J, M ller M, Picken M, et al. Carboxyl terminus of bovine papillomavirus type21 L1 protein is not required for capsid formation [J ]. Virology, 1996,223 (1) : [14 ] McLean C S, Churcher M J, Meinke J, et al. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus[j ]. J Clin Pathol, 1990,43 (6) : [15 ],,,. 58 [J ]. (Wang Li2Na, Song Wen2 Ling, Chen Wei, et al. Expression of the human papillomavirus type 58 capsid protein and preparation of it s antiserum [ J ]. Immunol), 2005,21 (4) : Chin J [16 ] Jenkins D. A review of cross2protection against oncogenic HPV by an HPV216Π18 AS042adjuvanted cervical cancer vaccine : importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention[j ]. Gynecol Oncol, 2008, 110(3 Suppl 1) :S182S25 [17 ] Moscicki A B. HPV vaccines : Today and in the future[j ]. J Adolesc Health, 2008,43 (4 Suppl) :S262S40 [18 ] Xu Y, Wang Q, Han Y, et al. Type2specific and cross2reactive antibodies induced by human papillomavirus 31 L1ΠL2 virus2like particles[j ]. J Med Microbiol, 2007,56(Pt7) :
2 HPV E1,E2,E4,E5,E6,E7 L1,L2 E6,E7 HPV HPV. Ciuffo Shope Jablonska HPV Zur Hausen HPV HPV16. HPV-genome.
58 2 pp.155-164 2008 2. HPV 20 HPV HPV HPV HPV HPV L1 HPV-DNA 16/18 2 HPV16 /18 6/11 4 2 100 1 Ciuffo 1907 20 Shope 1933 Raus 1934 20 70 Jablonska HPV Orth HPV5 8 1983 zur Hausen HPV16 1 HPV-genome 920-8641
More informationThe promise of HPV vaccines for Cervical (and other genital cancer) prevention
The promise of HPV vaccines for Cervical (and other genital cancer) prevention CONTROVERSIES IN OBSTETRICS GYNECOLOGY & INFERTILITY Barcelona March 27 F. Xavier Bosch Catalan Institute of Oncology CURRENT
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationProphylactic HPV vaccines: next generations
New Trends in Tumor Virology: Annecy Jan 19, 2010 Prophylactic HPV vaccines: next generations Lutz Gissmann l.gissmann@dkfz.de Conflict of interest LG is a consultant to GSK and Sanofi Pasteur MSD and,
More informationProduction of human papillomavirus type 45 virus-like particles in insect cells using a recombinant baculovirus
ELSEVIER FEMS Microbiology Letters 141 (1996) 111-116 MICROBIOLOGY LETTERS Production of human papillomavirus type 45 virus-like particles in insect cells using a recombinant baculovirus Abstract Antoine
More informationProphylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge
Prophylactic HPV Vaccines Margaret Stanley Department of Pathology Cambridge 8kb double stranded DNA viruses, absolutely host and tissue specific, Can t grow virus in tissue culture Classified by genotype
More informationClinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years
Clinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years Gudrun Maechler Director, Clinical & Medical Affairs Europe & Cervarix GSK Biologicals Presentation Outline HPV immunology Immunogenicity
More informationConflict of interest
Helsinki 2012 HPV vaccines for developing countries Lutz Gissmann l.gissmann@dkfz.de Conflict of interest LG is a consultant to GSK and Sanofi Pasteur MSD and, due to existing IP, receives royalties from
More informationINTRODUCTION HUMAN PAPILLOMAVIRUS
INTRODUCTION HUMAN PAPILLOMAVIRUS Professor Anna-Lise Williamson Institute of Infectious Disease and Molecular Medicine, University of Cape Town National Health Laboratory Service, Groote Schuur Hospital
More informationRESEARCH ARTICLE. Yue-Yun Wang 1, Li Li 2, Sheng Wei 2, Ji Peng 3, Shi-Xin Yuan 1, Jian-Sheng Xie 1, Zhi-Hua Liu 1 * Abstract.
RESEARCH ARTICLE Human Papillomavirus (HPV) Infection in Women Participating in Cervical Cancer Screening from 2006 to 2010 in Shenzhen City, South China Yue-Yun Wang 1, Li Li 2, Sheng Wei 2, Ji Peng 3,
More informationT he ability to generate human papillomavirus
COMMENTARY 961 Prophylactic HPV vaccines... Prophylactic HPV vaccines Margaret Stanley... Two HPV L1 VLP vaccines have been developed, providing protection for at least 5 years and reducing the risk of
More informationHPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions
HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions Douglas R. Lowy Laboratory of Cellular Oncology, National Cancer Institute, NIH,
More informationEffect of Chronic Aluminum Exposure on PKC, CaMK and Neurogranin in Hippocampus of Rat
ISSN 100727626 CN 1123870ΠQ 2007 5 Chinese Journal of Biochemistry and Molecular Biology 23 (5) :410 414 PKC CaMK Ng 3,,,,,, (, 110001) (long2term potentiation, LTP) C (protein kinase c, PKC) Ca 2 + 2
More informationSGM. Journal of General Virology (1994), 75, Printed in Great Britain 2075
Journal of General Virology (1994), 75, 2075 2079. Printed in Great Britain 2075 Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationHUMAN PAPILLOMAVIRUS VACCINES AND CERVICAL CANCER
HUMAN PAPILLOMAVIRUS VACCINES AND CERVICAL CANCER Virology The Human Papillomavirus (HPV) is a relatively small virus, belonging to the family Papillomaviridae, containing circular double-stranded DNA
More informationProphylactic human papillomavirus vaccines
Review series Prophylactic human papillomavirus vaccines Douglas R. Lowy and John T. Schiller Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland,
More information(51) Int Cl.: A61K 39/12 ( ) C12N 15/09 ( ) C12N 15/37 ( ) C12N 7/04 ( )
(19) (11) EP 1 588 713 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention of the grant of the patent: 22.12. Bulletin /51 (51) Int Cl.: A61K 39/12 (06.01) C12N 15/09 (06.01) C12N
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More informationFollowing microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells
Following microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells Virion Assembled Virus Stratified squamous epithelium Virion Suprabasal cells HPV DNA replication
More informationIdentification of Microbes Lecture: 12
Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCan genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?
Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine? Joakim Dillner and Darron R. Brown Human papillomavirus (HPV) infection is the cause of squamous cell carcinoma
More informationTSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet
Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 TSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet Details
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationE E Hepatitis E SARS 29, Lancet. E A B Enterically-Transmitted Non-A, Hepatitis E. Virus HEV nm. 1.35g/cm s ALT AST HEV HEV
7850 2004 Hepatitis E Tian-Cheng LI Naokazu TAKEDA Tatsuo MIYAMURA SARS 8 Lancet E E E Hepatitis E VirusHEV E E HEV HEV E 1955 29,000 E E A A B Enterically-Transmitted Non-A, Non-B Hepatitis 1983 Balayan
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationPrevalence of human papillomavirus infection of 65,613 women in East China
Ge et al. BMC Public Health (2019) 19:178 https://doi.org/10.1186/s12889-019-6487-9 RESEARCH ARTICLE Open Access Prevalence of human papillomavirus infection of 65,613 women in East China Yanmei Ge 1,
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationReceived 12 November 2010/Returned for modification 2 December 2010/Accepted 7 January 2011
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2011, p. 418 423 Vol. 18, No. 3 1556-6811/11/$12.00 doi:10.1128/cvi.00489-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Human Papillomavirus
More informationCommonly asked questions on human papillomavirus vaccine
Hong Kong J. Dermatol. Venereol. (2008) 16, 12-17 Review Article Commonly asked questions on human papillomavirus vaccine PKS Chan Recently, human papillomavirus (HPV) vaccine has been attracting the attention
More informationOrganization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles
Journal of General Virology (5),, 0-. Printed in Great Britain 0 Organization of the major and minor capsid proteins in human papillomavirus type virus-like particles Martin Sapp, l* Christoph Volpers,
More informationA Short Review on Human Papillomavirus Vaccines
A Short Review on Human Papillomavirus Vaccines KF TAM MRCOG HYS NGAN FRCOG Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong,
More informationHPV vaccine perspectives Dr. David Prado Cohrs
HPV vaccine perspectives Dr. David Prado Cohrs Universidad Francisco Marroquín, Guatemala President of the Sexually Transmitted Diseases Committee, SLIPE Disclosure statement The presenter has received
More informationHPVE7 oncoproteins as new markers for detection of cervical cancer and precancer
HPVE7 oncoproteins as new markers for detection of cervical cancer and precancer Dr. Pidder Jansen-Dürr Innsbruck University Innsbruck, Austria p.jansen-duerr@uibk.ac.at Human Papillomaviruses (HPVs) and
More informationVaccinology 101 for Fellows
Vaccinology 101 for Fellows Meg Fisher, MD Medical Director, The Children s Hospital Monmouth Medical Center An affiliate of the Saint Barnabas Health Care System Long Branch, NJ Disclosures I have no
More informationCERVICAL CANCER VACCINE DEVELOPMENT
Sexual Health for Marian Saville due 30 th November. CERVICAL CANCER VACCINE DEVELOPMENT Ian H Frazer The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationPrevention strategies against the human papillomavirus: The effectiveness of vaccination
Available online at www.sciencedirect.com Gynecologic Oncology 107 (2007) S19 S23 www.elsevier.com/locate/ygyno Prevention strategies against the human papillomavirus: The effectiveness of vaccination
More informationAn update on the Human Papillomavirus Vaccines. I have no financial conflicts of interest. Case 1. Objectives 10/26/2016
An update on the Human Papillomavirus Vaccines Karen Smith-McCune Professor, UCSF Department of Obstetrics, Gynecology and Reproductive Sciences John Kerner Endowed Chair I have no financial conflicts
More informationInnovations in Human Papillomavirus Vaccine
Oct 2014 Life Health Innovations in Human Papillomavirus Vaccine Innovation 1 Topics 1. Current HPV vaccines 2. New development 3. What s next? 2 PART I CURRENT HPV VACCINES 3 Worldwide incidence of cervical
More informationRecombinant VP60 in the form of virion-like particles as a potential vaccine against rabbit hemorrhagic disease virus *
Vol. 53 No. 2/2006, 371 376 Regular paper on-line at: www.actabp.pl Recombinant VP60 in the form of virion-like particles as a potential vaccine against rabbit hemorrhagic disease virus * Beata Gromadzka
More informationSubunit Rotavirus Vaccine Administered Parenterally to Rabbits Induces Active Protective Immunity
JOURNAL OF VIROLOGY, Nov. 1998, p. 9233 9246 Vol. 72, No. 11 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Subunit Rotavirus Vaccine Administered Parenterally
More informationUp date. sexually transmission HPV HPV HPV. high-risk HPV HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66, 68 HPV
Up date Kei Kawana HPV HPV HPV HPV HPV6, 11 HPV HPV HPV vaccine preventable diseasevpd HPV HPV HPV DNA 8 HPV 100 genomic type HPV HPV HPV HPV HPV 1 sexually transmission HPV HPV 2 HPV high-riskhpv HPV16,
More informationProphylactic HPV vaccines: Reducing the burden of HPV-related diseases
Vaccine 24S1 (2006) S1/23 S1/28 Prophylactic HPV vaccines: Reducing the burden of HPV-related diseases Luisa Lina Villa Ludwig Institute for Cancer Research, Sao Paulo branch Rua Prof. Antônio Prudente,
More information(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)
Supplementary Figure 1. Functional enrichment analyses of secretomic proteins. (a) Significant biological processes (upper panel) and disease biomarkers (lower panel) 2 involved by hrab37-mediated secretory
More informationSupplementary Information
Supplementary Information HBV maintains electrostatic homeostasis by modulating negative charges from phosphoserine and encapsidated nucleic acids Authors: Pei-Yi Su 1,2,3, Ching-Jen Yang 2, Tien-Hua Chu
More informationRabies virus-like particles expressed in HEK293 cells
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Rabies virus-like particles expressed in HEK293 cells Diego Fontana Cell Culture Laboratory
More informationIslet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot
Islet viability assay and Glucose Stimulated Insulin Secretion assay Islet cell viability was determined by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay using CellTiter
More informationHPV, Cancer Genes, and Raising Expectations
HPV, Cancer Genes, and Raising Expectations Douglas R. Lowy Laboratory of Cellular Oncology, Center for Cancer Research National Cancer Institute, National Institutes of Health Keynote Lecture, IFCPC World
More informationHow do we compare? IP724/BMTRY Introduction to Global and Public Health. Feb 21, 2012 Basic Science Rm Sharon Bond, PhD, CNM
Eradicating Cervical Cancer: Our Global Imperative College of Nursing February 2012 What is cervical cancer? Why do we care? 2 nd leading cause of cancer deaths among women worldwide (after breast ca)
More informationCervical cancer is the second most common cancer affecting women worldwide. Cervical
Continuing Education Column Human Papillomavirus Vaccine Mi-Kyung Kim, MD Jae Hong No, MD Yong -Sang Song, MD Department of Obstetrics and Gynecology, Seoul National University College of Medicine E -
More informationRotavirus Virus-Like Particles Administered Mucosally Induce Protective Immunity
JOURNAL OF VIROLOGY, Nov. 1997, p. 8707 8717 Vol. 71, No. 11 0022-538X/97/$04.00 0 Copyright 1997, American Society for Microbiology Rotavirus Virus-Like Particles Administered Mucosally Induce Protective
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationPromise of reduced HPV associated
HPV accounts for ~500,000 cases of cancer annually across the globe Promise of reduced HPV associated cancers in AIAN communities NAOMI LEE, PHD NIH IRACDA POSTDOCTORAL FELLOW UNIVERSIT OF NEW MEXICO Human
More informationNew paradigm for prevention of cervical cancer
European Journal of Obstetrics & Gynecology and Reproductive Biology 130 (2007) 25 29 Expert opinion New paradigm for prevention of cervical cancer GlaxoSmithKline has developed a bivalent vaccine, Cervarix
More informationJ. D. Trujillo,* N. M. Kumpula-McWhirter, K. J. Hötzel, M. Gonzalez, and W. P. Cheevers
JOURNAL OF VIROLOGY, Sept. 2004, p. 9190 9202 Vol. 78, No. 17 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.17.9190 9202.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Glycosylation
More informationHPV vaccination: the promise & problems
Review Article Indian J Med Res 130, September 2009, pp 322-326 vaccination: the promise & problems R. Sankaranarayanan Screening Group, International Agency for Research on Cancer, Lyon, France Received
More informationTarget Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
More informationGetting the Most Out of Baculovirus. Linda Lua
Getting the Most Out of Baculovirus Linda Lua Enabling World Class Research Recombinant Protein Production Discovery, Translational, Preclinical Drug discovery, vaccinology, diagnostics, functional materials,
More informationSystemic immunization with papillomavirus Li protein completely
Proc. Natl. Acad. Sci. USA Vol. 92, pp. 11553-11557, December 1995 Immunology Systemic immunization with papillomavirus Li protein completely prevents the development of viral mucosal papillomas JOANN
More informationGSK Cervical Cancer Vaccine:
GSK Cervical Cancer Vaccine: Overview of Clinical Data Jovelle B. Laoag-Fernandez, M.D., Ph.D., FPOGS Regional Medical Affairs HPV Vaccines GSK Biologicals Asia Pacific, Australasia, China/Hong Kong, Japan
More informationJyotika Sharma, Feng Dong, Mustak Pirbhai, and Guangming Zhong*
INFECTION AND IMMUNITY, July 2005, p. 4414 4419 Vol. 73, No. 7 0019-9567/05/$08.00 0 doi:10.1128/iai.73.7.4414 4419.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Inhibition
More informationReview Article. Abstract. Introduction. HPV Pathogenesis:
Review Article Prevention of human papilloma virus infection with vaccines Faisal Azam, Mohammad Shams-ul-Islam Medical Oncology, Churchill Hospital, Oxford, United Kingdom. Abstract Human Papilloma virus
More informationCervical screening. Cytology-based screening programmes
HPV-FASTER: broadening the scope for prevention of HPV-related cancer Combining the complementary approaches of HPV vaccination and screening could accelerate declines in the burden of cervical cancer
More informationLargest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing
FOR IMMEDIATE RELEASE Largest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing virus types Published in The Lancet: Additional efficacy could
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cervarix suspension for injection Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2. QUALITATIVE
More informationBattle against Human Papilloma Virus (HPV): Expanded Vaccine Recommendations
Battle against Human Papilloma Virus (HPV): Expanded Vaccine Recommendations Sean W. Clark, Pharm.D. PGY-2 Ambulatory Care Resident Duquesne University and The Center for Pharmacy Care I have no relevant
More informationCERVARIX GlaxoSmithKline
CERVARIX GlaxoSmithKline International Data Sheet. Version 2 (31/01/2007) Cervarix 1. Name of the medicinal product CervarixTM Human Papillomavirus vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted).
More informationChapter 12: Prophylactic HPV vaccines: Underlying mechanisms
Vaccine 24S3 (2006) S3/106 S3/113 Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms Margaret Stanley a,, Douglas R. Lowy b, Ian Frazer c a Department of Pathology, University of Cambridge, Tennis
More informationElectron Microscopy Imaging Reveals Unique Higher Order Structures of Adalimumab-TNFα and Infliximab-TNFα Complexes
Electron Microscopy Imaging Reveals Unique Higher Order Structures of Adalimumab-TNFα and Infliximab-TNFα Complexes Siew Leong Chan Protein Analytics, AbbVie Bioresearch Center Worcester MA Acknowledgement
More informationHPV vaccines. Margaret Stanley* MB PhD Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK
Best Practice & Research Clinical Obstetrics and Gynaecology Vol. 20, No. 2, pp. 279 293, 2006 doi:10.1016/j.bpobgyn.2005.10.011 available online at http://www.sciencedirect.com 5 HPV vaccines Margaret
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCervical Cancer 8/20/2008. New genital HPV infections are commonest amongst young adults. Development of antibody to HPV capsids after HPV infection
Preventing cervical cancer from bench to bedside and beyond Ian Frazer Diamantina Institute, The University of Queensland, Brisbane, Australia Cervical Cancer Second commonest cause of cancer in women
More informationPRODUCT INFORMATION GARDASIL 9. [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant]
PRODUCT INFORMATION GARDASIL 9 [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant] DESCRIPTION GARDASIL 9 *, Human Papillomavirus 9-valent Vaccine, Recombinant,
More informationTrehalose, sucrose and raffinose are novel activators of autophagy in human. keratinocytes through an mtor-independent pathway
Title page Trehalose, sucrose and raffinose are novel activators of autophagy in human keratinocytes through an mtor-independent pathway Xu Chen 1*, Min Li 1*, Li Li 1, Song Xu 1, Dan Huang 1, Mei Ju 1,
More informationReceived 11 March 1997/Returned for modification 16 May 1997/Accepted 3 June 1997
INFECTION AND IMMUNITY, Aug. 1997, p. 3328 3336 Vol. 65, No. 8 0019-9567/97/$04.00 0 Copyright 1997, American Society for Microbiology Human Papillomavirus Type 16 Virus-Like Particles Expressed in Attenuated
More informationChinese Journal of Biochemistry and Molecular Biology . 40 % FAS mgπml ( ) ; FAS
ISSN 100727626 CN 1123870ΠQ 2003 6 Chinese Journal of Biochemistry and Molecular Biology 19 (3) :297 304,, ( 100039) 3 (FAS), FAS FAS 40 % FAS 0 005 mgπml ( ) ; 0146 mgπml 015 min 50 % 32 min 90 % FAS,
More informationOncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy
Oncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy Jianhua Chen, Pei Gao, Sujing Yuan, Rongxin Li, Aimin Ni, Liang Chu, Li Ding, Ying Sun, Xin-Yuan Liu, Yourong
More informationB. SDS-PAGE. Western blot MW (kda) Supplementary Information. Supplementary Figure 1. MW (kda) Glutelin. Prolamin. 3 E.coli. 3 E.
Supplementary Information Supplementary Figure 1. A. MW (kda) B. SDS-PAGE Western blot MW (kda) 50 40 100 75 50 37 30 Glutelin 25 20 15 20 Prolamin 10 ARP1 1 2 3 E.coli MucoRice ARP1 (RNAi +) 4 5 ARP1
More informationObjective 3. Develop new and improved diagnostic tools, vaccines, and novel management approaches
Objective 3. Develop new and improved diagnostic tools, vaccines, and novel management approaches Development of novel nanoparticle-base vaccines for infectious bronchitis PI, Mazhar I. Khan; CoPI, Peter
More informationT H E J O U R N A L O F C E L L B I O L O G Y
Supplemental material Edens and Levy, http://www.jcb.org/cgi/content/full/jcb.201406004/dc1 T H E J O U R N A L O F C E L L B I O L O G Y Figure S1. Nuclear shrinking does not depend on the cytoskeleton
More informationSupporting Information
Supporting Information Pang et al. 10.1073/pnas.1322009111 SI Materials and Methods ELISAs. These assays were performed as previously described (1). ELISA plates (MaxiSorp Nunc; Thermo Fisher Scientific)
More informationSupplementary Information
Supplementary Information Supplementary Figure 1. CD4 + T cell activation and lack of apoptosis after crosslinking with anti-cd3 + anti-cd28 + anti-cd160. (a) Flow cytometry of anti-cd160 (5D.10A11) binding
More informationEpidemiological Features of Human Papillomavirus (HPV) Infection among Women Living in Mainland China
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.7.4015 MINI-REVIEW Epidemiological Features of Human Papillomavirus (HPV) Infection among Women Living in Mainland China Jing Li 1,2&, Rong Huang 1,2&, Johannes
More informationBone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by
Nakano et al. Supplementary information 1. Supplementary Figure 2. Methods 3. References Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into
More informationHPV FREE IDAHO. Fundamentals of HPV Bill Atkinson, MD MPH
HPV FREE IDAHO Fundamentals of HPV Bill Atkinson, MD MPH You are the Key to HPV Cancer Prevention William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition February
More informationSV40 Detection and Transmission: Does SV40 Circulate in Human Communities?
SV40 Detection and Transmission: Does SV40 Circulate in Human Communities? Keerti Shah, Dana Rollison and Raphael Viscidi Johns Hopkins Medical Institutions Baltimore, MD Background A large number of cancer
More informationRESEARCH COMMUNICATION
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.4.1519 Prevalence and Genotype Distribution of Human Papillomavirus Infection in Women Attending Hospitals in Chaozhou RESEARCH COMMUNICATION Prevalence and
More informationBMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice
SUPPLEMENTARY MATERIALS BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice Elena Corradini, Paul J. Schmidt, Delphine Meynard, Cinzia Garuti, Giuliana
More informationCan HPV, cervical neoplasia or. HIV transmission?
Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical
More informationLaboratory Considerations
Laboratory Considerations In Support of HPV Vaccine Programs Elizabeth R. Unger PhD, MD Team Leader HPV Laboratory Centers for Disease Prevention and Control Towards Comprehensive Cervical Cancer Control:
More informationHPV Life Cycle & Vaccination: Possible Relevance for HSV Vaccines
HPV Life Cycle & Vaccination: Possible Relevance for HSV Vaccines Douglas R. Lowy Center for Cancer Research, NCI Deputy Director, NCI National Institutes of Health Herpes Virus Infection & Immunity Meeting
More informationTargeted disruption of influenza A virus hemagglutinin in genetically modified. mice reduces viral replication and improves disease outcome
Supplementary Information Targeted disruption of influenza A virus hemagglutinin in genetically modified mice reduces viral replication and improves disease outcome Song Wang 1#, Chao Chen 1#, Zhou Yang
More informationdengue virus DENV DENV-1 DENV-2 DENV-3 DENV-4 NS1 Non-structural protein 1 NS1 DENV antibody-dependent enhancement ADE DENV
2018 9 59 17 Journal of Traditional Chinese Medicine 2018 Vol. 59 No. 17 1523 DOI 10. 13288 /j. 11-2166 /r. 2018. 17. 021 1 1 dengue virus DENV A B C 2009 WHO 1 2014 2 3 2018 DENV 1 antibody-dependent
More informationQuadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil Ò )
ADIS DRUG EVALUATION Drugs 2010; 70 (18): 2449-2474 0012-6667/10/0018-2449/$55.55/0 ª 2010 Adis Data Information BV. All rights reserved. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
More informationThe subcortical maternal complex controls symmetric division of mouse zygotes by
The subcortical maternal complex controls symmetric division of mouse zygotes by regulating F-actin dynamics Xing-Jiang Yu 1,2, Zhaohong Yi 1, Zheng Gao 1,2, Dan-dan Qin 1,2, Yanhua Zhai 1, Xue Chen 1,
More informationSupporting information
Electronic Supplementary Material (ESI) for RSC Advances. This journal is The Royal Society of Chemistry 2014 Supporting information Experimental Section Synthesis and modification of SBA-15. In a typical
More information